Technology | Interventional Radiology | August 14, 2019

FDA Clears NvisionVLE Imaging System for Pancreatic and Biliary Applications

New application follows previous clearance of optical coherence tomography system for esophageal applications

FDA Clears NvisionVLE Imaging System for Pancreatic and Biliary Applications

Image courtesy of NinePoint Medical

August 14, 2019 — NinePoint Medical Inc. announced it has received U.S. Food and Drug Administration (FDA) clearance to market the NvisionVLE Imaging System for use in the pancreas and bile duct. These anatomical indications add to the previously existing esophageal applications for NinePoint’s optical coherence tomography (OCT) imaging platform.

The NvisionVLE Imaging System provides physicians real-time, high-resolution volumetric images of the tissue surface and subsurface. This allows gastroenterologists to thoroughly evaluate tissue for regions of interest that may not be visible with other medical imaging technologies. The newly cleared application is associated with NinePoint’s Low-Profile Optical Probe, a 7 French diameter imaging probe designed to handle small and tortuous anatomies, such as those found in the pancreatico-biliary system. In the pancreas and bile duct, the ability to see beneath the tissue surface could help physicians answer a number of important clinical questions.

“When a patient enters our care with an undiagnosed condition in the pancreatico-biliary system, the stakes can be very high,” said Isaac Raijman, M.D., previously the chief of gastroenterology at Baylor St. Luke’s Medical Center. “We have a number of tools today to help evaluate a patient’s condition within this anatomy. Unfortunately in many cases, our current toolset is unable to provide enough information to determine the best course of action. This is especially concerning for strictures or blockages of unknown origin. We are hopeful and excited that imaging beneath the surface with the NinePoint technology will supply the missing link and will enhance our clinical decision-making for these critically ill patients.”

This clearance marks another significant step for the strategic collaboration between NinePoint Medical and their exclusive worldwide distributor, Merit Medical Systems Inc. 

The pancreatico-biliary clearance marks a productive 12 months of product development activity for NinePoint Medical, according to the company. In November of 2018, NinePoint announced the first FDA-cleared artificial intelligence imaging technology for gastroenterology applications, the Intelligent Real-time Image Segmentation (IRIS) product. 

For more information: www.ninepointmedical.com

Related Content

NinePoint Medical Receives Additional FDA 510(k) Clearance for NvisionVLE Imaging System

Related Content

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers.

Technology | Angiography | September 17, 2019
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems...
Adept Medical Launches Antegrade IR Platform
Technology | Interventional Radiology | September 03, 2019
New Zealand-based Adept Medical announced the launch of the Antegrade IR Platform. Clinically driven, it is placed to...
Study Finds Growth in Paracentesis and Thoracentesis Procedures

Image source: Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. [CC BY 3.0 (https://creativecommons.org/licenses/by/3.0)]

News | Interventional Radiology | August 27, 2019 | Jeff Zagoudis, Associate Editor
A new Harvey L. Neiman Health Policy Institute study assesses temporal and patient-level differences in paracentesis...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Boston Scientific Closes Acquisition of BTG plc
News | Interventional Radiology | August 20, 2019
Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere
News | Interventional Radiology | July 31, 2019
New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have...
WVU Medicine Installs First Alphenix 4D CT in the U.S.
News | CT Angiography (CTA) | July 24, 2019
The West Virginia University (WVU) Heart and Vascular Institute is the first hospital in the country to acquire the...
Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...